Inhibition of MMP-2 gelatinolysis by targeting exodomain-substrate interactions

Xiaoping Xu, Zhihua Chen, Yao Wang, Lynda Bonewald, Bjorn Steffensen

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

MMP-2 (matrix metalloproteinase 2) contains a CBD (collagen-binding domain), which is essential for positioning gelatin substrate molecules relative to the catalytic site for cleavage. Deletion of the CBD or disruption of CBD-mediated gelatin binding inhibits gelatinolysis by MMP-2. To identify CBD-binding sites on type I collagen and collagen peptides with the capacity to compete CBD binding of gelatin and thereby inhibit gelatinolysis by MMP-2, we screened a one-bead one-peptide combinatorial peptide library with recombinant CBD as bait. Analyses of sequences from the CBD-binding peptides pointed to residues 715-721 in human α1(I) collagen chain as a binding site for CBD. A peptide (P713) including this collagen segment was synthesized for analyses. In SPR (surface plasmon resonance) assays, the CBD and MMP-2E404A, a catalytically inactive MMP-2 mutant, both bound immobilized P713 in a concentration-dependent manner, but not a scrambled control peptide. Furthermore, P713 competed gelatin binding by the CBD and MMP-2E404A. In control assays, neither of the non-collagen binding alkylated CBD or MMP-2 with deletion of CBD (MMP-2ΔCBD) bound P713. Consistent with the exodomain functions of the CBD, P713 inhibited ∼90% of the MMP-2 gelatin cleavage, but less than 20% of the MMP-2 activity on a peptide substrate (NFF-1) which does not require the CBD for cleavage. Confirming the specificity of the inhibition, P713 did not alter MMP-2ΔCBD or MMP-8 activities. These experiments identified a CBD-binding site on type I collagen and demonstrated that a corresponding synthetic peptide can inhibit hydrolysis of type I and IV collagens by competing CBD-mediated gelatin binding to MMP-2.

Original languageEnglish (US)
Pages (from-to)147-155
Number of pages9
JournalBiochemical Journal
Volume406
Issue number1
DOIs
StatePublished - Aug 15 2007
Externally publishedYes

Fingerprint

Matrix Metalloproteinase 2
Collagen
Substrates
Gelatin
Peptides
Matrix Metalloproteinases
Collagen Type I
Binding Sites
Assays
Peptide Library
Collagen Type IV
Surface Plasmon Resonance
Surface plasmon resonance

Keywords

  • Collagen
  • Collagen-binding domain (CBD)
  • Exodomain
  • Gelatinolysis
  • Matrix metalloproteinase 2 (MMP-2)
  • Matrix metalloproteinase inhibitor

ASJC Scopus subject areas

  • Biochemistry
  • Medicine(all)

Cite this

Inhibition of MMP-2 gelatinolysis by targeting exodomain-substrate interactions. / Xu, Xiaoping; Chen, Zhihua; Wang, Yao; Bonewald, Lynda; Steffensen, Bjorn.

In: Biochemical Journal, Vol. 406, No. 1, 15.08.2007, p. 147-155.

Research output: Contribution to journalArticle

Xu, Xiaoping ; Chen, Zhihua ; Wang, Yao ; Bonewald, Lynda ; Steffensen, Bjorn. / Inhibition of MMP-2 gelatinolysis by targeting exodomain-substrate interactions. In: Biochemical Journal. 2007 ; Vol. 406, No. 1. pp. 147-155.
@article{f3709900c30a409786b98acf1b4036ff,
title = "Inhibition of MMP-2 gelatinolysis by targeting exodomain-substrate interactions",
abstract = "MMP-2 (matrix metalloproteinase 2) contains a CBD (collagen-binding domain), which is essential for positioning gelatin substrate molecules relative to the catalytic site for cleavage. Deletion of the CBD or disruption of CBD-mediated gelatin binding inhibits gelatinolysis by MMP-2. To identify CBD-binding sites on type I collagen and collagen peptides with the capacity to compete CBD binding of gelatin and thereby inhibit gelatinolysis by MMP-2, we screened a one-bead one-peptide combinatorial peptide library with recombinant CBD as bait. Analyses of sequences from the CBD-binding peptides pointed to residues 715-721 in human α1(I) collagen chain as a binding site for CBD. A peptide (P713) including this collagen segment was synthesized for analyses. In SPR (surface plasmon resonance) assays, the CBD and MMP-2E404A, a catalytically inactive MMP-2 mutant, both bound immobilized P713 in a concentration-dependent manner, but not a scrambled control peptide. Furthermore, P713 competed gelatin binding by the CBD and MMP-2E404A. In control assays, neither of the non-collagen binding alkylated CBD or MMP-2 with deletion of CBD (MMP-2ΔCBD) bound P713. Consistent with the exodomain functions of the CBD, P713 inhibited ∼90{\%} of the MMP-2 gelatin cleavage, but less than 20{\%} of the MMP-2 activity on a peptide substrate (NFF-1) which does not require the CBD for cleavage. Confirming the specificity of the inhibition, P713 did not alter MMP-2ΔCBD or MMP-8 activities. These experiments identified a CBD-binding site on type I collagen and demonstrated that a corresponding synthetic peptide can inhibit hydrolysis of type I and IV collagens by competing CBD-mediated gelatin binding to MMP-2.",
keywords = "Collagen, Collagen-binding domain (CBD), Exodomain, Gelatinolysis, Matrix metalloproteinase 2 (MMP-2), Matrix metalloproteinase inhibitor",
author = "Xiaoping Xu and Zhihua Chen and Yao Wang and Lynda Bonewald and Bjorn Steffensen",
year = "2007",
month = "8",
day = "15",
doi = "10.1042/BJ20070591",
language = "English (US)",
volume = "406",
pages = "147--155",
journal = "Biochemical Journal",
issn = "0264-6021",
publisher = "Portland Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Inhibition of MMP-2 gelatinolysis by targeting exodomain-substrate interactions

AU - Xu, Xiaoping

AU - Chen, Zhihua

AU - Wang, Yao

AU - Bonewald, Lynda

AU - Steffensen, Bjorn

PY - 2007/8/15

Y1 - 2007/8/15

N2 - MMP-2 (matrix metalloproteinase 2) contains a CBD (collagen-binding domain), which is essential for positioning gelatin substrate molecules relative to the catalytic site for cleavage. Deletion of the CBD or disruption of CBD-mediated gelatin binding inhibits gelatinolysis by MMP-2. To identify CBD-binding sites on type I collagen and collagen peptides with the capacity to compete CBD binding of gelatin and thereby inhibit gelatinolysis by MMP-2, we screened a one-bead one-peptide combinatorial peptide library with recombinant CBD as bait. Analyses of sequences from the CBD-binding peptides pointed to residues 715-721 in human α1(I) collagen chain as a binding site for CBD. A peptide (P713) including this collagen segment was synthesized for analyses. In SPR (surface plasmon resonance) assays, the CBD and MMP-2E404A, a catalytically inactive MMP-2 mutant, both bound immobilized P713 in a concentration-dependent manner, but not a scrambled control peptide. Furthermore, P713 competed gelatin binding by the CBD and MMP-2E404A. In control assays, neither of the non-collagen binding alkylated CBD or MMP-2 with deletion of CBD (MMP-2ΔCBD) bound P713. Consistent with the exodomain functions of the CBD, P713 inhibited ∼90% of the MMP-2 gelatin cleavage, but less than 20% of the MMP-2 activity on a peptide substrate (NFF-1) which does not require the CBD for cleavage. Confirming the specificity of the inhibition, P713 did not alter MMP-2ΔCBD or MMP-8 activities. These experiments identified a CBD-binding site on type I collagen and demonstrated that a corresponding synthetic peptide can inhibit hydrolysis of type I and IV collagens by competing CBD-mediated gelatin binding to MMP-2.

AB - MMP-2 (matrix metalloproteinase 2) contains a CBD (collagen-binding domain), which is essential for positioning gelatin substrate molecules relative to the catalytic site for cleavage. Deletion of the CBD or disruption of CBD-mediated gelatin binding inhibits gelatinolysis by MMP-2. To identify CBD-binding sites on type I collagen and collagen peptides with the capacity to compete CBD binding of gelatin and thereby inhibit gelatinolysis by MMP-2, we screened a one-bead one-peptide combinatorial peptide library with recombinant CBD as bait. Analyses of sequences from the CBD-binding peptides pointed to residues 715-721 in human α1(I) collagen chain as a binding site for CBD. A peptide (P713) including this collagen segment was synthesized for analyses. In SPR (surface plasmon resonance) assays, the CBD and MMP-2E404A, a catalytically inactive MMP-2 mutant, both bound immobilized P713 in a concentration-dependent manner, but not a scrambled control peptide. Furthermore, P713 competed gelatin binding by the CBD and MMP-2E404A. In control assays, neither of the non-collagen binding alkylated CBD or MMP-2 with deletion of CBD (MMP-2ΔCBD) bound P713. Consistent with the exodomain functions of the CBD, P713 inhibited ∼90% of the MMP-2 gelatin cleavage, but less than 20% of the MMP-2 activity on a peptide substrate (NFF-1) which does not require the CBD for cleavage. Confirming the specificity of the inhibition, P713 did not alter MMP-2ΔCBD or MMP-8 activities. These experiments identified a CBD-binding site on type I collagen and demonstrated that a corresponding synthetic peptide can inhibit hydrolysis of type I and IV collagens by competing CBD-mediated gelatin binding to MMP-2.

KW - Collagen

KW - Collagen-binding domain (CBD)

KW - Exodomain

KW - Gelatinolysis

KW - Matrix metalloproteinase 2 (MMP-2)

KW - Matrix metalloproteinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=34547850671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547850671&partnerID=8YFLogxK

U2 - 10.1042/BJ20070591

DO - 10.1042/BJ20070591

M3 - Article

VL - 406

SP - 147

EP - 155

JO - Biochemical Journal

JF - Biochemical Journal

SN - 0264-6021

IS - 1

ER -